PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q2–2026Q1) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Orientbio continues to face flat revenue and operating losses in its core laboratory-animal and preclinical CRO business, while attempting a structural pivot through the revived OND-1 hair-growth drug candidate and an AI-based CRO platform.
Annual revenue has stayed range-bound between roughly KRW 26.3bn and 29.4bn from 2022 to 2025, with operating losses recorded in three of the four years.
Net income has swung sharply from year to year due to one-off items such as valuation gains or losses on held equity stakes, alternating between profit and loss from 2022 through 2025.
A 2-for-1 share consolidation carried out in May 2026 lifted the stock above the coin-stock threshold, but listing-maintenance issues such as market-cap requirements still warrant ongoing monitoring.
The hair-growth candidate OND-1 has shifted its delivery approach, secured patent registration in Korea and Japan, and is undergoing primate toxicity testing ahead of a planned Phase 2 trial.
Global regulatory shifts, including the US FDA's roadmap to reduce animal testing, are creating structural headwinds for the core lab-animal and CRO business.
Orientbio traces its roots to Orient Watch Industrial, founded in 1959, and pivoted from watchmaking—spun off in 2005—into laboratory animal production and preclinical R&D.
Leveraging a technology alliance with Charles River Laboratories of the United States, the company produces International Genetic Standard (IGS) barrier-raised rodents, guinea pigs, beagles, and primates for domestic pharmaceutical companies, biotech ventures, and research institutions, operating the Gapyeong Center 1 and 2 as the country's largest breeding facility.
The company recently integrated the production and quality-management systems of the two Gapyeong centers to improve operating efficiency.
Primates are produced at a Cambodia-based center run by subsidiary OrientCam, giving the group a structure in which it is the only private Korean company capable of primate CRO work.
Preclinical contract research (CRO) is handled by subsidiary Orient Genia, and because both the animal-supply and CRO businesses sit within the same laboratory-animal industry, revenue diversification is described as limited.
Market reporting indicates that roughly 65% of cumulative revenue for the April-December 2025 period came from laboratory animal supply.
As new growth drivers, the company is pursuing the OND-1 hair-growth drug candidate and building an AI-based preclinical prediction platform that combines primate life-cycle data with its CRO capabilities.
Competitively, the company maintains its technology tie-up with global majors such as Charles River while holding a long-standing domestic position, though a scale gap with large overseas CROs persists.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q1 | ₩7.7B | -₩1.6B | −21.1% |
| 2025Q2 | ₩6.9B | -₩700M | −9.8% |
| 2025Q3 | ₩8.6B | -₩1.6B | −18.2% |
| 2025Q4 | ₩6.2B | ₩800M | 12.9% |
| 2026Q1 | ₩6.6B | ₩50,062,912 | 0.8% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩26.3B | -₩3.8B | ₩34.2B | −14.4% | 41.1% | 26.2% |
| 2023 | ₩28.8B | ₩1.5B | -₩12.4B | 5.0% | −17.4% | 13.5% |
| 2024 | ₩28B | -₩600M | ₩12.9B | −2.3% | 15.1% | 14.0% |
| 2025 | ₩29.4B | -₩3.1B | -₩13.2B | −10.5% | −18.4% | 18.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05
On a confirmed basis, Orientbio's annual revenue moved in a narrow, stagnant range: KRW 26.3bn in 2022, KRW 28.8bn in 2023, KRW 28.0bn in 2024, and KRW 29.4bn in 2025.
Operating profit/loss was KRW -3.8bn in 2022, +KRW 1.5bn in 2023, -KRW 0.6bn in 2024, and -KRW 3.1bn in 2025, with losses in three of the four years, and the 2025 operating margin of -10.5% widened from -2.3% the prior year.
Net income attributable to owners, by contrast, moved independently of operating results, swinging from +KRW 34.2bn in 2022 to -KRW 12.4bn in 2023, +KRW 12.9bn in 2024, and -KRW 13.2bn in 2025, a pattern interpreted as reflecting one-off valuation gains and losses on held equity or investment assets flowing through non-operating income.
On a quarterly basis, operating losses persisted through 2025 - KRW 1.62bn in Q1, KRW 0.68bn in Q2, and KRW 1.57bn in Q3 - before turning to an operating profit of KRW 0.80bn in Q4.
Yet net income in that same fourth quarter posted a large loss of KRW 9.09bn, underscoring a clear divergence between operating performance and bottom-line results.
In the first quarter of 2026, revenue was KRW 6.59bn with a small operating profit of KRW 0.05bn, while net income swung sharply positive to KRW 4.85bn, again a move presumed to stem from non-operating rather than core operating factors.
Owners' net income summed over the trailing four quarters (2025Q2-2026Q1) remained in loss territory at KRW -6.32bn.
On the cash-flow side, 2025 operating cash flow was a modest but positive KRW 0.75bn, and the debt ratio stood at 18.0%, staying below 30% across all four years, indicating that the balance sheet itself has been managed conservatively.
The laboratory-animal and preclinical CRO industry serves as essential infrastructure for drug and vaccine development, but recent global regulatory trends have created structural headwinds for the sector.
The US FDA began scaling back animal testing following the 2022 implementation of the FDA Modernization Act 2.0, and in April 2025 unveiled a roadmap to allow animal testing only in exceptional cases within three to five years.
In December of the same year, the FDA Modernization Act 3.0 passed the US Senate, laying an institutional foundation for alternative testing technologies such as organoids and organ-on-a-chip, which could constrain medium- to long-term growth in demand for laboratory animals themselves.
Domestically, the laboratory-animal business carries a strong national-infrastructure character, making it difficult to set supply prices purely on market logic; while many countries support or directly operate such infrastructure at the state level, private companies in Korea have largely borne this burden alone.
Orientbio is reported to have invested roughly KRW 30bn over ten years to maintain specific breeds such as beagles, reflecting structurally heavy fixed costs from long-cycle breeding.
Meanwhile, across the broader KOSPI and KOSDAQ pharma/bio sector, tightened coin-stock delisting rules and market-cap requirements that took effect from July 2026 have prompted numerous companies, including Orientbio, to undertake capital adjustments such as share consolidations or capital reductions.
Industry observers note that a share consolidation is only a short-term response to preserve listing status and is unlikely to be a fundamental solution unless followed by real improvement in business value.
The company positions the OND-1 hair-growth drug candidate at the core of its value-up strategy.
OND-1 has shifted its drug-delivery method from topical scalp application toward an oral formulation, following domestic patent registration in 2022 and Japanese patent registration completed in January 2026, with examinations now proceeding in major jurisdictions including the United States, China, the EU, and Hong Kong.
Testing is under way under a primate toxicity-study contract signed in January 2025 as a step toward Phase 2 entry, and the company has stated that no clear systemic toxicity or major organ abnormalities were observed in preclinical repeat-dose studies.
However, actual efficacy and safety can only be confirmed through future clinical trials, and the program remains at a stage prior to Phase 2 approval.
As a new growth driver, the company has flagged an AI-based preclinical prediction platform that combines primate life-cycle data with the CRO capabilities of subsidiary Orient Genia, envisioned as a service that would predict drug-candidate responses based on primate data once a pharmaceutical company inputs candidate information.
In the core business, the integration of the Gapyeong Center 1 and 2 operations is under way to improve cost efficiency, which the company aims to use to lift profitability in the animal-supply business.
On listing maintenance, the May 2026 2-for-1 share consolidation lifted the stock above the coin-stock threshold, but additional listing-maintenance criteria such as market-cap requirements remain an ongoing management item.
Because owners' net income summed over the trailing four quarters remains in loss territory, the price-to-earnings ratio is not meaningful in this window. The price-to-book ratio trades below 1x, indicating the market is valuing the shares at a discount to book net assets.
The company has not paid dividends in recent years, so dividend-related metrics are not established. Looking across multiple years, net income has alternated between losses and profits without establishing a clear trend, a pattern attributed more to non-operating factors than to underlying operating performance.
With a low debt ratio and a balance sheet close to debt-free, valuation discussions need to be considered alongside both the prospects for a recovery in growth and profitability and the ongoing listing-maintenance issues.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05
The debt ratio has stayed below 30% in every year from 2022 to 2025, reflecting a balance sheet close to debt-free. Operating cash flow in 2025 was modest but positive, confirming at least a minimal level of self-generated cash flow.
This financial soundness provides a base from which the company can absorb the long timelines required for drug development and facility investment.
After shifting its delivery approach toward an oral formulation, the OND-1 hair-growth candidate has completed patent registration in Korea and Japan, with examinations ongoing in the United States, China, the EU, and Hong Kong.
A primate toxicity study aimed at Phase 2 entry is under way, and the company has noted no clear systemic toxicity in preclinical repeat-dose testing. With Korea's hair-loss treatment market expanding, further clinical progress is cited as a variable for future company value.
An effort is under way to build an AI-based preclinical prediction service by combining primate life-cycle data with the CRO capabilities of subsidiary Orient Genia. This is interpreted as an attempt to diversify beyond the single revenue stream of laboratory animal supply into higher-value services.
The company's status as the only private domestic primate CRO operator, via its Cambodia-based center, underpins this effort.
Annual revenue has failed to break out of the KRW 26.3bn-29.4bn range from 2022 to 2025, with operating losses recorded in three of those four years (2022, 2024, 2025). The 2025 operating margin of -10.5% widened from the prior year, indicating that a recovery in core profitability has yet to materialize.
Given the long breeding cycles inherent to the business, fixed-cost burdens are heavy and pricing cannot be set purely by market logic.
In April 2025 the US FDA announced a roadmap to allow animal testing only in exceptional cases within three to five years, and in December of the same year the FDA Modernization Act 3.0 passed the US Senate, establishing an institutional basis for alternative testing technologies such as organoids.
This trend could pose a medium-to-long-term burden on Orientbio's business structure, in which laboratory animal supply and CRO account for the bulk of revenue. The pace and magnitude of any demand contraction will depend on how quickly alternative testing technologies are adopted.
Owners' net income has alternated between profit and loss every year from 2022 (profit) through 2025 (loss), and the 2024 profit is reported to have stemmed largely from valuation gains tied to a rise in the share price of Nasdaq-listed Innotiv, a holding of the company.
This structure, in which investment-asset value swings drive net income independent of operating results, raises uncertainty in forecasting performance.
A similarly large gap between operating results and net income reappeared in the fourth quarter of 2025 and the first quarter of 2026, suggesting continued influence from comparable non-operating factors.
The May 2026 2-for-1 share consolidation lifted Orientbio above the coin-stock threshold, but tightened market-cap requirements across both KOSPI and KOSDAQ mean additional listing-maintenance criteria must continue to be monitored.
If the share price falls again after consolidation, the risk of being designated an administrative issue could resurface, and observers note that meeting formal criteria through consolidation or capital reduction alone is not a fundamental solution. Without real business results, listing-maintenance pressure could recur.
OND-1 is a candidate whose development was halted after completing a domestic Phase 1 trial and later resumed; it remains at a stage prior to Phase 2 approval, so both the timing of trial entry and the eventual results remain uncertain.
The change in delivery method requires additional patent and preclinical procedures, and clinical trials typically demand long timelines and substantial cost. Failure or delay in drug development could undermine a core pillar of the company's value-up strategy.
Because net income is highly sensitive to valuation gains and losses on held equity and investment assets, movements in the share prices or market values of those assets can directly shock reported results.
This means factors unrelated to core operations can heavily sway net income at each earnings release, complicating investors' interpretation of performance, and similar non-operating swings cannot be ruled out going forward.
The Q3 2026 earnings disclosure should be checked for revenue and operating profit trends, and whether non-operating swings in net income recur.
Watch for results of the OND-1 primate toxicity study, any Phase 2 IND filing, and progress on US, Chinese, and EU patent examinations.
Continue to check whether the share price stays above the KRW 1,000 threshold and whether market-cap requirements are met, to monitor the risk of an administrative-issue designation.
Look for disclosures on partnerships or revenue generation tied to the AI-based preclinical prediction platform.
Orientbio has faced years of stagnant revenue and recurring operating losses within a largely single-track business structure centered on laboratory animal supply and preclinical CRO, while net income has swung sharply due to valuation gains and losses on investment assets unrelated to operating performance.
The May 2026 share consolidation lifted the stock above the coin-stock threshold, but listing-maintenance burdens such as market-cap requirements remain an ongoing item to manage.
Growth drivers put forward include the revived OND-1 hair-growth drug candidate and the buildout of an AI-based preclinical prediction platform, though both remain at an early stage with results not yet visible.
On the industry side, structural shifts such as the US FDA's roadmap to reduce animal testing could pose a medium-to-long-term burden on the core business. On the financial side, a low debt ratio and stable cash flow provide at least a minimal buffer.
Investors will want to watch whether core profitability recovers, how OND-1's clinical progress unfolds, and whether listing-maintenance requirements continue to be met.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.